<DOC>
	<DOCNO>NCT00088829</DOCNO>
	<brief_summary>RATIONALE : Analyzing gene change chemotherapy may help doctor predict patient 's response treatment help plan effective treatment . PURPOSE : This clinical trial study well genetic test work predict response paclitaxel woman unresected breast cancer .</brief_summary>
	<brief_title>Genetic Testing Predicting Response Paclitaxel Women With Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine feasibility accrue woman unresected infiltrate carcinoma breast clinical trial involve serial breast biopsy administration neoadjuvant paclitaxel formal assessment axillary lymph node status . - Determine standard protocol template gene microarray analysis , term time method collect tissue sample , administration neoadjuvant paclitaxel patient . - Determine safety efficacy tissue sample patient . Secondary - Identify gene ( ) gene cluster exhibit significant difference respond non-responding tumor treatment neoadjuvant paclitaxel patient . - Identify gene ( ) gene cluster exhibit change gene expression administration neoadjuvant paclitaxel patient . - Compare significant difference gene expression respond non-responding tumor patient treated drug . - Develop , preliminarily , statistical model utilize individual gene and/or gene cluster best predict response paclitaxel patient . OUTLINE : This pilot , multicenter study . Patients undergo core needle breast biopsy within 14 day start neoadjuvant paclitaxel treatment . Patients receive neoadjuvant paclitaxel IV 3 hour day 1 . Treatment repeat every 21 day 4 course absence disease progression unacceptable toxicity . Patients undergo core needle breast biopsy 48 hour first administration paclitaxel , upon completion course 1 , either upon completion last course ( patient clinical radiographic evidence residual disease ) definitive breast surgery . Biopsy sample analyze gene expression gene microarray analysis . Patients follow survival . PROJECTED ACCRUAL : A total 40 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Inclusion : Histologically confirm infiltrate carcinoma breast Unresected disease Highrisk ( &gt; 50 % risk relapse ) disease , include follow highrisk marker : Estrogen receptor progesterone receptor negative Palpable axillary lymph node Grade 3 histology S phase fraction &gt; 10 % Ki67 &gt; 30 % Disease warrant combination therapy doxorubicin , cyclophosphamide , paclitaxel HER2/neu negative positive Hormone receptor status : Not specify Menopausal status Known Performance status ECOG 02 Absolute neutrophil count &gt; 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Bilirubin ≤ 1 . 5 time normal ( except patient know Gilbert 's disease ) Creatinine ≤ 1.5 time normal Exclusion : uncontrolled congestive heart failure myocardial infarction within past 6 month unstable angina uncontrolled hypertension pregnant nursing serious bacterial , viral , fungal infection require ongoing treatment severe peripheral neuropathy poor psychiatric risk history know serious comorbid medical psychiatric condition prior cytotoxic therapy breast cancer</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>stage IA breast cancer</keyword>
	<keyword>stage IB breast cancer</keyword>
	<keyword>HER2-negative breast cancer</keyword>
	<keyword>HER2-positive breast cancer</keyword>
</DOC>